Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufacturing orga ...

Shares in Samsung Biologics rose 7.1 percent the previous day following reports of a possible spinoff and investor optimism about the move. Biologics counts tech giant Samsung Electronics and builder ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based pharmaceutical company. This latest deal adds to a string of partnerships ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

Samsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines ...